Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Insulin GZR4 vs Degludec and Icodec in Type 2 Diabetes
NCT07146347Phase 1Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GZR4 in type 2 diabetes mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Pharmacodynamics of GZR4 compared to insulin degludec at steady state. Started Aug 2025; status: recruiting.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07146347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146347.